Correction to: Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan

Lignende værker

• Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan
  af: Tanaka, Tetsuhiro, et al.
  Udgivet: (2018)
• Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan
  af: Hayashi, Terumasa, et al.
  Udgivet: (2020)
• Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial
  af: Hayashi, Terumasa, et al.
  Udgivet: (2020)
• Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration
  af: Takama, Hirotaka, et al.
  Udgivet: (2007)
• Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
  af: Kato, Hideki, et al.
  Udgivet: (2017)